Actively Recruiting
Study of Topical Tranexamic Acid to Reduce Bleeding During Elective Cesarean Delivery in Women Aged 18 to 51
Led by Wolfson Medical Center · Updated on 2026-07-02
112
Participants Needed
4
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether applying topical tranexamic acid TXA directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study focuses on pregnant women aged 18 to 51 undergoing elective cesarean delivery at term 37 weeks or more. It aims to see if topical TXA shortens uterine closure time and reduces the need for additional hemostatic sutures. Participants will be randomly assigned to receive either topical TXA or a placebo solution of normal saline sprayed onto the uterine incision during surgery. The TXA dose consists of 500 mg diluted in 15 mL saline applied after placental delivery and before each layer of uterine closure. Both groups will undergo standard cesarean procedures and postoperative care, ensuring consistent surgical techniques. During the study, researchers will collect clinical data including operative details, hemoglobin levels, use of extra hemostatic measures, length of hospital stay, and any maternal or newborn complications. Safety monitoring will check for blood clots, allergic reactions, and infections. The main measurements are uterine closure time and the number of extra sutures needed during surgery, with follow-up up to 30 days after delivery.
CONDITIONS
Brief Title
Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery
Research Team
L
Liat Mor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here